Recursion Pharmaceuticals
RXRX
158 hedge funds and large institutions have $841M invested in Recursion Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 32 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
72% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 32
65% more call options, than puts
Call options by funds: $633K | Put options by funds: $383K
10% more funds holding
Funds holding: 144 → 158 (+14)
0.66% more ownership
Funds ownership: 68.1% → 68.76% (+0.66%)
12% less capital invested
Capital invested by funds: $953M → $841M (-$111M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.95M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$4.08M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.02M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.79M |
| 5 |
Citigroup
New York
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11.9M |
| 2 |
AG
Artal Group
Luxembourg
|
-$7.4M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.86M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.53M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.31M |
RXRX Hedge Fund Activity: Q1 2023 in Review
158 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2023, worth a combined $841M — down 12% from $953M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RXRX positions and 14 closed out — a net gain of 15 holders — while 55 added to existing stakes and 32 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.95M. The largest seller was State Street, cutting an estimated $11.9M.
- 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2023, up from 144 in Q4 2022.
- Funds reported $841M of Recursion Pharmaceuticals stock for Q1 2023, down 12% quarter-over-quarter.
- 29 funds opened new Recursion Pharmaceuticals positions in Q1 2023 and 14 closed out, a net change of +15 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $6.95M added.
- The largest Recursion Pharmaceuticals seller in Q1 2023 was State Street, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2023.